Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian T Tsuji

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
Antimicrobial Agents and Chemotherapy|May 13, 2020
Polymyxin Triple Combinations against Polymyxin-Resistant, Multidrug-Resistant, KPC-Producing Klebsiella pneumoniaeSu Mon Aye, Irene Galani, Heidi Yu, et al.
Mbio|July 27, 2017
Polymyxin Combinations Combat <i>Escherichia coli</i> Harboring <i>mcr-1</i> and <i>bla</i><sub>NDM-5</sub>: Preparation for a Postantibiotic EraZackery P Bulman, Liang Chen, Thomas J Walsh, et al.
Clinical Pharmacokinetics|June 25, 2018
Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic FibrosisJürgen B Bulitta, Yuanyuan Jiao, Stefanie K Drescher, et al.
The Journal of Antimicrobial Chemotherapy|May 29, 2020
Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection modelThomas P Lodise, Nicolas M Smith, Nick O'Donnell, et al.
Pharmaceuticals (Basel, Switzerland)|June 27, 2025
Pharmacodynamic Evaluation of Adjuvant Targets: Low Molecular Weight PBP7/8 Effects on β-Lactam Activity Against Carbapenem-Resistant Acinetobacter BaumanniiBrian M Ho, Jingxiu Jin, Jacob T Sanborn, et al.
The Lancet. Microbe|July 1, 2022
Research priorities towards precision antibiotic therapy to improve patient careZackery P Bulman, Sebastian G Wicha, Elisabet I Nielsen, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2012
The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic modelZakuan Z Deris, Heidi H Yu, Kathryn Davis, et al.
Antimicrobial Agents and Chemotherapy|April 17, 2019
Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled TrialsYuanyuan Jiao, Bartolome Moya, Mong-Jen Chen, et al.
The Journal of Antimicrobial Chemotherapy|September 17, 2016
High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumanniiJustin R Lenhard, Jürgen B Bulitta, Terry D Connell, et al.
Antimicrobial Agents and Chemotherapy|August 4, 2022
Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane IntegrityNicholas M Smith, Katie Rose Boissonneault, Liang Chen, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
Antimicrobial Agents and Chemotherapy|May 13, 2020
Polymyxin Triple Combinations against Polymyxin-Resistant, Multidrug-Resistant, KPC-Producing Klebsiella pneumoniaeSu Mon Aye, Irene Galani, Heidi Yu, et al.
Mbio|July 27, 2017
Polymyxin Combinations Combat <i>Escherichia coli</i> Harboring <i>mcr-1</i> and <i>bla</i><sub>NDM-5</sub>: Preparation for a Postantibiotic EraZackery P Bulman, Liang Chen, Thomas J Walsh, et al.
Clinical Pharmacokinetics|June 25, 2018
Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic FibrosisJürgen B Bulitta, Yuanyuan Jiao, Stefanie K Drescher, et al.
The Journal of Antimicrobial Chemotherapy|May 29, 2020
Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection modelThomas P Lodise, Nicolas M Smith, Nick O'Donnell, et al.
Pharmaceuticals (Basel, Switzerland)|June 27, 2025
Pharmacodynamic Evaluation of Adjuvant Targets: Low Molecular Weight PBP7/8 Effects on β-Lactam Activity Against Carbapenem-Resistant Acinetobacter BaumanniiBrian M Ho, Jingxiu Jin, Jacob T Sanborn, et al.
The Lancet. Microbe|July 1, 2022
Research priorities towards precision antibiotic therapy to improve patient careZackery P Bulman, Sebastian G Wicha, Elisabet I Nielsen, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2012
The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic modelZakuan Z Deris, Heidi H Yu, Kathryn Davis, et al.
Antimicrobial Agents and Chemotherapy|April 17, 2019
Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled TrialsYuanyuan Jiao, Bartolome Moya, Mong-Jen Chen, et al.
The Journal of Antimicrobial Chemotherapy|September 17, 2016
High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumanniiJustin R Lenhard, Jürgen B Bulitta, Terry D Connell, et al.
Antimicrobial Agents and Chemotherapy|August 4, 2022
Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane IntegrityNicholas M Smith, Katie Rose Boissonneault, Liang Chen, et al.
Pageof 11